Urogen Pharma Ltd (OQ:URGN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 9 Ha'ta'asiya St
RA'ANANA 4365007
Tel: 1-609-4603588
Website: https://www.urogen.com
IR: See website
<
Key People
Elizabeth A. Barrett
President, Chief Executive Officer, Director
Dong Kim
Chief Financial Officer
Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Mark P. Schoenberg
Chief Medical Officer
   
Business Overview
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Financial Overview
For the fiscal year ended 31 December 2023, Urogen Pharma Ltd revenues increased 29% to $82.7M. Net loss decreased 7% to $102.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development Expenses, Net decrease of 13% to $43.7M (expense), INTEREST AND OTHER (INCOME) EXPENSES, NE increase from $938K to $2.6M (income).
Employees: 198 as of Jan 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $457.38M as of Dec 31, 2023
Annual revenue (TTM): $82.71M as of Dec 31, 2023
EBITDA (TTM): -$64.71M as of Dec 31, 2023
Net annual income (TTM): -$102.24M as of Dec 31, 2023
Free cash flow (TTM): -$76.57M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 34,122,087 as of Mar 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.